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Azithromycin (AZ) is a broad-spectrum antibiotic with anti-inflammatory and anti-quorum sensing 
activity against biofilm forming bacteria such as Pseudomonas aeruginosa (Pa). AZ administered by 
oral or parenteral routes however, neither efficiently access nor remain in therapeutic doses inside 
pulmonary biofilm depths. Instead, inhaled nanocarriers loaded with AZ may revert the problem of low 
accessibility and permanence of AZ into biofilms, enhancing its antimicrobial activity.  The first inhalable 
nanovesicle formulation of AZ: nanoarchaeosome-AZ (nanoARC-AZ) is here presented. NanoARC 
prepared with total polar archaeolipids (TPA, rich in 2,3-di-O-phytanyl-sn-glycero-1-phospho-(3'-sn-
glycerol-1'-methylphosphate) (PGP-Me) from Halorubrum tebenquichense archaebacteria, consisted of  
 180 nm diameter nanovesicles, loaded with 0.28 w:w AZ:TPA. NanoARC-AZ displayed lower MIC and 
MBC, higher preformed biofilm disruptive and anti-PAO1 activity in biofilm than AZ. NanoARC 
penetrated and disrupted the structure of PAO1 biofilm within only 1 h.  2 mL of 15 g/mL AZ nanoARC-
AZ nebulized along 5 min rendered AZ doses compatible with in vitro antibacterial activity.  The strong 
association between AZ and nanoARC bilayer, combined electrostatic attraction and trapping into 
perpendicular methyl groups of archaeolipids, as determined by Laurdan fluorescence anisotropy, 
generalized polarization and SAXS, was critical to stabilize during storage and endure shear forces of 
nebulization. NanoARC-AZ was non-cytotoxic on A549 cells and human THP-1 derived macrophages, 
deserving further preclinical exploration as enhancers of AZ anti-PAO1 activity. 
Keywords: inhalation, archaeolipid bilayer, antibiotic trapping
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Azithromycin (AZ) is an azalide subclass of macrolide (a semi-synthetic 9- N-methylation 
derivative of erythromycin), with broad-spectrum antibiotic activity against gram-positive, gram-negative, 
and atypical bacterial infections that lead to pneumonia.1,2 AZ is approved by the U.S. Food and Drug 
Administration (FDA) against pneumonia and chronic obstructive pulmonary disease exacerbations.2 
The in vivo effects of AZ combine antibacterial, bronchodilatation and importantly, anti-inflammatory 
activities (by supressing the activation of NF-kB and the synthesis of proinflammatory cytokines IL-6 and 
IL-8).3 The use of AZ extends also to treat chronic lung diseases, where reducing the impact of infection, 
inflammation and subsequent tissue injury is of major importance.4 AZ in particular, is administered 
against inflammatory recurrent chronic airways infections caused by Pseudomonas aeruginosa (Pa) 5,6 
occurring in  cystic fibrosis (CF)7,8, diffuse panbronchiolitis9 and bronchiectasis.10  Long-term treatment 
with AZ for instance, is included in the current guidelines for CF patients aged ≥ 6 years.11  
Either to treat pneumonia or chronic lung inflammations, AZ is administered by oral or parenteral 
routes.12,4 These systemic routes, however, lead to off-target diffusion, poor bioavailability and, 
consequently, higher doses to attain the necessary concentrations in the lung, especially in the epithelial 
lining fluid.13 
The inhalatory route constitutes a direct pathway to airways, that circumvents the problem of the 
poor penetration of intravenously administered antibiotics into lung parenchymal tissue and bronchial 
secretions. It also provides a fast action onset, minimizing the access to circulation and therefore to the 
generation of unwanted systemic effect.14 Indeed, different to the intravenous, the inhalatory route is 
compatible with chronic administration of medicines.15 AZ moreover, has got poor gastric tolerability in 
the long term use.16,17 In view of such circumstances, inhalable formulations of AZ are expected to 
improve current therapies against lung infections.    
The principal weakness of inhaled antibiotics against by Pa infections, however, is the low 
antibiotic exposure in the vicinity of biofilm colonies, a fact that results in diminished anti-pseudomonal 
efficacy after repeated uses. A suitable nanocarrier for AZ may help to overcome such drawbacks, 
because of their ability to modify drug’s pharmacokinetics, biodistribution and pharmacodynamics (if 
needed), to selective and efficiently delivery drugs to diseased targets. To that aim however, 
nanocarriers structure must be tuned as a function of target site and administration route.18 
Not surprisingly, nanocarriers have started to attract interest as tools to improve the therapeutic 
index of inhalable antibiotics.  Examples of that are the nebulized liposomal ciprofloxacins Pulmaquin 
and Lipoquin19, developed by Aradigm20, and  Arikayce, a liposomal amikacin developed by Insmed.21,22 
Arikayce is the first and only medication approved by the FDA for the treatment of Mycobacterium avium 
complex (MAC) lung disease, as part of a combination antibacterial drug regimen for adult patients who 
have limited or no alternative treatment options.23 Remarkably, liposomes are the only nanocarriers 
customized for nebulization, that made it to advanced clinical trials and received FDA approval.  The 
mucus penetrating character of these liposomes enables a prolonged permanence of the antibiotic in 
the airways, reducing the number of daily administrations. 24
Despite of the promising avenue opened by inhalable liposomes however, no inhalable liposomal 
AZ formulations have yet been developed. Approaches based on non-lipid nanocarriers, such as N-
fumaroylated diketopiperazine (FDKP) microparticles were recently reported to be used for pulmonary 
delivery of AZ (AZ@FDKP-MPs), for example. FDKP is an FDA approved, inert excipient used as the 
primary component in Afrezza® to assist in the delivery of recombinant human insulin via inhalation.25,26 
Compared to intravenous injection and oral administration, intratracheal insufflation of AZ@FDKP-MPs 
achieved at least a 3.4 times higher local concentration and prolonged retention times.13 On the other 
hand, the performance of a liposomal AZ formulation against Pa was recently reported to display higher 
activity than AZ against biofilm forming Pa in vitro; the structural features of these liposomes or their 
administration route however, were not specified.27 Importantly, the structure of nebulized liposomes 
must be tailored to avoid structural lability upon nebulization and storage, by adding- as exemplified by 
Lipoquin and Arikayce bilayers composition -, high proportions of high phase transition temperature 
lipids, such as HSPC or DPPC, respectively. 28,29
Nanoarchaeosomes (nanoARC) are soft nanovesicles made of innovative biomaterials, polar 
lipids extracted from sources other than animal, vegetable, or bacteria: the hyperhalophilic 
archaebacteria Halorubrum tebenquichense.   NanoARC are highly resistant to physical-chemistry and 
enzymatic attacks30,31 and are also naturally targeted to cells expressing SRA1 (Scavenger receptor 
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Class AI) nanovesicles,  because of their high content on the double negatively charged 
phosphoarchaeolipid 2,3-di-O-phytanyl-sn-glycero-1-phospho-(3'-sn-glycerol-1'-methylphosphate 
(PGP-Me),  a ligand for SRA1.32 Recently, we showed that archaeolipids moieties of nebulized pH-
sensitive nanoARC used to deliver anti-inflammatory agents to alveolar macrophages, provided higher 
structural endurance to nebulization stress and storage,  than liposomes  made of ordinary 
phospholipids.32 Because of such benefits, the performance of nanovesicles entirely or partly made of 
archaeolipids as alternatives to liposomes, is thus worth to be explored. In this work, we hypothesize 
that AZ loaded nebulized nanoARC made of archaeolipids from H. tebenquichense (nanoARC-AZ), may 
display competitive structural advantages compared to AZ and liposomal AZ. The results showed that 
nanoARC-AZ, a lacking Chol cholesterol and hydrogenated lipids formulation, proved to be structurally 
stable upon storage, nebulization, and quickly penetrated PAO1 biofilm displaying higher anti-Pa activity 
than AZ. 
2. Materials and methods
2.1 Materials
1,2-Hydrogenated-L-α-phosphatidylcholine (HSPC) was from Northern Lipids Inc, Vancouver, 
Canadá.  Azithromycin dihydrate, cholesterol, 6-Dodecanoyl-N,N-dimethyl-2-naphthylamine (Laurdan), 
3-(4,5-dimetiltiazol- 2-yl)-2,5-diphenyl tetrazolium bromide (MTT), phorbol 12-13-acetate (PMA) and 2-
mercaptoethanol and mucin from porcine stomach type III were from Sigma-Aldrich (MO, USA). 
Lissamine™rhodamine B 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine triethylammonium 
salt (RhPE), Hoechst 33342, Roswell Park Memorial Institute 1640 (RPMI), Dulbecco’s Modifed Eagle 
Medium (DMEM), penicillin-streptomycin sulphate, glutamine, sodium pyruvate and 
trypsin/ethylenediamine tetra acetic acid were from Gibco® Life Technologies (NY, USA), fetal bovine 
serum (FBS) was from Internegocios (Buenos Aires, Argentina). Tryptic soy broth (TSB), bacteriological 
agar and Mueller Hinton Broth (MHB) were acquired from Britania, Buenos Aires, Argentina. The other 
reagents were of analytic grade from Anedra, Research AG (Buenos Aires, Argentina).  
2.2 Archaebacteria growth, extraction and characterization of total polar archaeolipids 
(TPA)
Halorubrum tebenquichense archaea, isolated from soil samples of Salina Chica, Península de 
Valdés and Chubut, Argentina was grown in basal medium supplemented with yeast extract and 
glucose. 33 Biomass was grown in 16.5-L medium in a 25-L homemade stainless-steel bioreactor at 
40°C and harvested 72 h after growth. TPA were extracted from biomass using the Bligh and Dyer 
method modified for extreme halophiles.34 Between 500 and 700 mg TPA were isolated from each 
culture batch. The reproducibility of each TPA-extract composition was routinely screened by phosphate 
content35 and ESI–MS, as described in Higa et al 2012.36
2.3 Preparation of AZ-nanovesicles 
Conventional nanoliposomes (HSPC:Chol 3:1 w:w, nanoL), nanoL loaded with AZ 
(HSPC:Chol:AZ at 0.75:0.25:0.4 and 0.75:0.25:1 w:w, nanoL-AZ),  nanoarchaeosomes (TPA, 
nanoARC) and, nanoARC loaded with AZ (TPA:AZ at 1:0.4 and  1:1 w:w, nanoARC-AZ) were prepared 
by the film hydration method. Briefly, mixtures of lipids dissolved in chloroform: methanol 1:1 v/v and AZ 
dissolved in methanol were mixed in round bottom flasks and were rotary evaporated at 40°C until 
elimination of the solvent. The film was flushed with N2 and hydrated with aqueous phase (10 mM Tris 
buffer pH 7.4 with 0.9% w: w, NaCl-Tris buffer) up to a final concentration of 10 mg/mL of total lipids 
(TL). The resultant suspensions were sonicated (1 h with a bath-type sonicator 80 W, 80 kHz) and 
extruded 10-times through two stacked polycarbonate membranes of 0.4 and 0.2 μm pore size using a 
100 mL Thermobarrel extruder (Northern Lipids, Burnaby, Canada). The resulting nanovesicles were 
sterilized by passage through a 0.22-μm sterile filter, and stored at 4°C.
To prepare RhPE labelled nanovesicles, RhPE was added at 0.5% weight to the organic lipid 
solutions, and lipid films were hydrated with NaCl-Tris buffer as stated above.
2.4 Structural characterization of AZ-nanovesicles 
Phospholipids were quantified by a colorimetric phosphate microassay.35
AZ was quantified by acid derivatization according to Haleem et al.37 First, samples were 
disrupted with 200 µL methanol, then 1000 µL hydrochloric acid 11 N was added, and samples were 
refluxed at 60°C in a water bath for 30 minutes and absorbance was measured at 482 nm. The standard 
curve was linear in the range of 15 – 100 µg/mL of AZ, with correlation coefficient of 0.9866 ± 0.0042.
 RhPE was quantified by spectrofluorometry (ex = 561 nm and em = 580 nm) using the 
fluorescence spectrometer LS Perkin Elmer upon complete disruption of 1 volume of nanovesicles in 40 
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volumes of methanol. The fluorescence intensity (I) of the sample was compared using a standard curve 
prepared with RhPE in methanol. The standard curve was linear in the range of 0.075–0.5 µg/mL RhPE 
with a correlation coefficient of 0.9939 ± 0.0025. 
Size and ζ potential were determined by dynamic light scattering and phase analysis light 
scattering, respectively, using a nanoZsizer apparatus (Malvern Instruments, Malvern, UK).
Cryo-electron microscopy (Cryo-EM) was performed at National Laboratory of Nanotechnology 
(LNNano) at CNPEM - Campinas, São Paulo. A 300 mesh Holey Lacey Carbon grid from Ted Pella® 
was used, the grids were submitted to a glow discharge procedure (Pelco easiGlow discharge system -
Ted Pella, USA) (15 mA for 10 seconds) in order to increase its hydrophilicity. Then grids were inserted 
in a Vitrobot® (Mark IV, Thermo Fischer Scientific, USA) where 3 µL of sample were added, it was given 
20 s for sample fixation. Subsequently, an automatic blotting (blot force=-5, blot total=3) was performed 
to dry the excess of sample. Finally, the grid was rapidly plunged into liquid ethane wrapped into a liquid 
nitrogen environment. Measurements were made in a TALOS F200C (Thermo Fischer Scientific, USA) 
microscope at 200 kV with a CMOS camera Ceta 16M 4K x 4K (Thermo Fischer Scientific, USA). 
ImageJ® software (National Institutes of Health, 1987) was used to image manipulation.
The order and fluidity of the nanovesicles bilayer with or without AZ were assessed by determining the 
Laurdan generalized polarization (GP) and fluorescence anisotropy (FA) in the nanovesicles. 
Nanovesicles were labelled with Laurdan by mixing 10 µL of 120 mM Laurdan in methanol with a volume 
of nanovesicles sufficient to render a 1: 20 mol: mol Laurdan: lipid ratio. GP was calculated using the 
following equation:
𝐺𝑃 =
𝐼440 ―  𝐼490
𝐼440 + 𝐼490
where I440 and I490 are the fluorescence intensities at em =440 nm and em = 490 nm, 
respectively, obtained from the spectra between 400 and 520 nm at ex = 364 nm (slit ex: 5.0 nm and 
slit em: 10.0 nm. Scan speed: 100 nm min/1). FA was calculated using the fluorimeter software 
according to the following equation:
𝐹𝐴 =
𝐼0 ―  𝐺𝐼90
𝐼0 + 2𝐺𝐼90
  
where I0 and I90 are the fluorescence intensities at em = 440 nm with ex = 364 nm, and the 
excitation polarizer is oriented at 0 and 90° respectively. The correction factor G was obtained from the 
ratio of emission intensity at 0 and 90°, with the excitation polarizer oriented at 90° (after the subtraction 
of scattered light).
Small angle x ray scattering (SAXS) measurements were performed at the SAXS1 beam line in 
the Brazilian Synchrotron Light Laboratory, (LNLS- Campinas, São Paulo, Brazil). The X-ray wavelength 
was λ=1.488 Å, and the sample-to-detector distance was ~1000 mm, allowing a q-range of 0.1 < q < 4 
. A bidimensional detector was used (Pilatus 300K). Samples were measured in a mica sample 𝑛𝑚 ―1
holder, with a 1 mm spacer, temperature was set to 22.0 ± 0.5 °C and controlled with a water bath. Data 
was collected for 100 s and checked for radiation damage (by measuring consecutive frames). Herein 
no radiation damage effect was observed during the experiments. Finally, curves were subtracted from 
the buffer’s contribution and normalized by samples’ attenuation.
In order to get more information on the scattering curves of this vesicles in the absence and presence 
of AZ, the uni- and multilamellar model for lipidic vesicles were used (S. 1).38,39 
2.5 Antimicrobial activity of AZ-nanovesicles
2.5.1 Bacterial strains
Staphylococcus aureus ATCC 25923 (S. aureus) and P.a. P. aeruginosa PAO1 were grown in 
lysogeny broth (LB) medium in shaking incubator at 37°C and 200 rpm for 18 h until bacterial cultures 
grew into log phase with optical densities (OD600) ranging from 0.6-0.8. 
2.5.2 Minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) 
assay 
MICs were determined by using the broth microdilution assay following the Clinical and Laboratory 
Standards Institute recommendations.40 Two-fold serial dilutions of AZ or AZ-nanovesicles were made 
in cation-adjusted MHB (CAMHB) and added in 96 wells plates. The bacteria inoculum was diluted in 
CAMHB to obtain a suspension containing approximately 5 x 105 colony-forming unit (CFU)/mL and the 
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plates were incubated for 24 h at 37°C. The MIC was defined as the lowest concentration that completely 
prevented cell growth detected by the unaided eye.  
MBCs were determined by inoculating the wells with samples concentrations above the MIC, on 
LB agar plates and incubating for 24 h at 37°C. MBC was defined as the lowest concentration producing 
a 99.9% reduction in CFU relative to the initial inoculum. 
2.5.3 Inhibition of biofilm formation
Inhibition of biofilm development was assayed in 96-wells flat-bottom polystyrene plates.  AZ or 
AZ-nanovesicles were two-fold serially diluted in CAMHB and then the bacterial inoculum was added to 
reach a final concentration of 5x105 CFU/ml, with a final volume of 100 µL per well.  Plates were 
incubated at 37°C for 24 h. Media alone or media with inoculum were used as negative and positive 
control, respectively. To determine the amount of biofilm, after incubation the supernatant was gently 
removed, and the formed biofilms were washed twice with 100 µL of saline solution to withdraw 
planktonic cells. The remaining biofilm was fixed with 100 µL of 100 % methanol for 15 min, and then 
stained with 100 µL of crystal violet 1% (v/v) for 5 min. The dye was removed and washed twice with 
200 µL of distilled water, and the plate was dried at 37°C for 30 min. Finally, 100 µL of 33% (v/v) acetic 
acid was added, samples were homogenized by gentle agitation and absorbance was measured in a 
microplate reader at 595 nm.
2.5.4 Disruption of pre-formed biofilm and bacterial viability 
Biofilms were developed in 96-wells flat-bottom polystyrene plates with CAMHB broth for 24 h. 
Then, the supernatant was removed and 100 µl of fresh media with two-fold serial dilutions of AZ or AZ-
nanovesicles were added to each well. Plates were incubated for other 24 h at 37°C. Two identical 
plates were prepared for each experiment. One was used for biofilm quantification by the same crystal 
violet staining method described above. The other was used to analyze cell viability within biofilm by the 
formazan dye-based MTT assay. For this purpose, media was gently removed, and biofilms were 
washed three times with 200 µL of saline. Then, 100 µL of MTT 0.05 % (w/v) was added to each well 
and plates were incubated at 37°C in the dark for 3 h. After incubation, the supernatant was withdrawn, 
and formazan crystals were dissolved with 100 µL of dimethyl sulfoxide and homogenized by orbital 
agitation for 10 min. The absorbance was measured at 570 nm. 
2.5.5 Lipase and protease inhibition assays
The bacteria lipase and protease activity were determined as describe Solleti et al.27 Briefly, AZ 
and AZ-nanovesicles were diluted in CAMHB at a concentration of 0.25 and 0.5 µg/mL of AZ and 
transferred in 2 mL tubes. PAO1 suspension was added to the tubes at a final concentration of 
approximately 5 x 105 CFU/mL. Tubes were incubated for 24 h at 37°C and 200 rpm. After 24 h, OD600 
of each tube was measured; supernatants were collected by centrifugation at 16,000 g and filter 
sterilized. 
For lipase assay a 0.3 mL aliquot of supernatant, 0.3 mL of Tween 20 in NaCl-Tris buffer, 50 µL 
of CaCl2 (1 M) and 0.6 mL H2O were mixed in a 2 mL tube and incubated at 37°C for 24 h with agitation 
at 200 rpm. The presence of lipase was measured by turbidity at OD400. For protease assay, 150 µL of 
the supernatants were added to the hole of Petri dishes with 25 mL of 2% agar containing 3% skimmed 
milk and incubated for 48 h at 37°C. The presence of protease was determined by measuring the 
diameter of the zone of clearance around the holes with calipers.
2.6 Interaction between AZ-nanovesicles and mucins 
2.6.1 Nanovesicles size and  potential in mucins solution
A mucin  solution (mucin at 2.5 % w/v in 8.18 g/L NaCl and 0.37 g/L KCl, pH 741 was diluted to 1 
mg/mL and incubated with nanovesicles to obtain a relation of 1:1 w:w of mucin:nanovesicles (at a final 
ratio of 500 µg/mL mucins and 500 µg/mL TL) at 37º C and 200 rpm for 1 h; after that size and zeta 
potential were determined.42
2.6.2 Nanovesicles diffusion through mucins solution
A quantitative diffusion study was performed according to 43,44 using the Transwell system as a 
two-compartment system. Briefly, 24-wells plates (ThinCert™) with 3 µm pore diameter polyester 
membrane and occupying a surface of 33.6 mm2 were covered with 30 mg of mucin solution. The donor 
chamber was filled with 0.8 mL of RhPE-labelled nanovesicles at 0.5 mg/mL TL in phosphate buffer 
saline pH 7.2 (PBS). The final mucin concentration was 15 mg/mL in donor chamber. The acceptor 
compartment was filled with 0.850 mL PBS. The whole plate was covered with a plate lid and incubated 
at 37°C on an orbital shaker at 300 rpm. At predetermined time points of 0, 1, 4, 10 and 20 h, 100 µL 
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volumes were removed from the acceptor compartment and replaced by same volume of preheated 
buffer. The fluorescence intensity of RhPE was measured as stated above.
Percentage of diffusion (D) of RhPE-labelled nanovesicles across the mucin layer was calculated 




where I+MUC = fluorescence intensity in the acceptor compartment after incubation in the presence 
of mucins and I-MUC= fluorescence intensity in the acceptor compartment after incubation in the absence 
of mucins.
2.7 Interaction between nanovesicles and bacteria
2.7.1 Adhesion between nanovesicles and planktonic bacteria
Flow cytometry was used to evaluate nanovesicles-bacterium interactions according to Mugabe 
et al 2006. Aliquots of overnight bacterial cultures were diluted in phosphate-buffered saline (PBS) and 
incubated with 25 µg/mL of RhPE-nanovesicles, with or without 5 mg/mL of mucins or PBS alone 
(control) at 37°C, 200 rpm during 1 h. The samples were centrifuged through a sucrose cushion, washed 
twice, and fixed with 1% paraformaldehyde. Triplicate samples were then analyzed with FACSCalibur 
(BectonDickinson, San José, CA, USA). Data were analyzed using Flowing Software 2.5.1 (Finland). 
2.7.2 Anti- P. aeruginosa activity in the presence of mucins
Bactericidal activities were determined by the microbroth dilution technique. The bacterial strain 
PAO1 was diluted in CAMHB to obtain 5x105 CFU/mL and transferred to 96-well plates. PAO1 was 
exposed to different dilutions of AZ and AZ-nanovesicles with or without 5 mg/mL of mucins. The plates 
were incubated for 24 h at 37°C. After incubation, each sample was inoculated on agar plates and 
incubated for 24 h at 37°C to evaluate bacterial growth by determine CFU/mL
2.7.3 Nanovesicles penetration in P. aeruginosa biofilm 
To visualize nanovesicles distribution on bacterial biofilm, confocal microscopy analysis was 
performed according to Dong et al.45 Briefly, PAO1 biofilm was grown on Nunc™ Lab-Tek™ II Chamber 
Slide™ (Invitrogen) for 24 h in MHB. Afterwards, the bacterial biofilm on the culture slide was rinsed 
twice with saline solution to remove the planktonic cells and incubated with RhPE-nanovesicles at 0.5 
mg/mL for 1 h and 24 h at 37 °C. Saline solution was applied as the non-treatment control. Biofilms were 
washed three times with saline solution and stained with 2 µg/mL of Hoechst 33342 for 15 min at room 
temperature for detection of bacteria. After three washes, biofilms were fixed with glutaraldehyde (5% 
in PBS). After removing the upper chamber of the culture slide, the samples were sealed with glycerol 
and ready to be examined under confocal microscope (Olympus FV1000, Japan) with an emission filter 
of 575–675 nm for RhPE detection (laser 559 nm) and 430–455 nm for Hoechst 33342 detection (laser 
405 nm). An objective of 20X (XLUMPLFLN-W) with a NA of 1 was used. For each sample, three 
representative z-stacks containing the full thickness of biofilm with nanovesicles were captured and 
experiments were repeated twice. The image processing and analysis were carried out by the software 
Olympus cell Sens image analysis software v6.3 and three dimensional (3D) reconstructions were 
generated using Fiji Software.46
The penetration of nanovesicles within the biofilm was measured as the relative fluorescence 
intensity (RFI): RFI = FI RhPE / FF Hoechst   
2.8 Cytotoxicity of AZ-nanovesicles of human cells
The human epithelial lung cell line A549 (ATCC® CCL-185™) was bought from Asociación Banco 
Argentino de Células and were maintained in MEM supplemented with 10 and 20% of FBS, 100 U/mL 
penicillin, 100 μg/mL streptomycin and 2 mM L-glutamine in a humidified atmosphere of 5% CO2 at 
37°C. Dr Barrionuevo Paula (Instituto de Medicina Experimental, Buenos Aires, Argentina) supplied the 
human monocyte cell line THP-1 (ATCC TIB-202™). The cells were maintained in complete RMPI 
medium supplemented with 0.05 mM 2-mercaptoethanol and 1 mM sodium pyruvate. THP-1, 
monocytes, were differentiated into macrophages by treatment with 100 ng/mL PMA for 24 h. 
The viability of cells upon 24 h incubation with empty and with AZ nanovesicles was measured 
by the MTT assay. Briefly, THP-1 and A549 cells were seeded in 96-well plates with a density of 4 × 104 
cells per well and grown for 24 h. Then, cells were incubated with series of different concentration of 
empty nanovesicles (20, 60, 180 and 900 µg/mL of TL), AZ and AZ-nanovesicles (5, 15, 45 and 225 
μg/mL of AZ). After 24 h of incubation the medium was removed, cells were washed with PBS and 110 
μl of 5 mg/mL MTT solution was added to each well. After 3 hours of incubation, the MTT solution was 
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removed, the insoluble formazan crystals were dissolved in dimethyl sulfoxide, and absorbance was 
measured at 570 nm in a Cytation™ 5 Cell Imaging Multi-Mode Reader BioTek Instruments (VT, USA). 
The cell viability was expressed as a percentage of the cells grown in medium.
2.9 Stability of AZ-nanovesicles upon nebulization
The structural stability of nanovesicles upon nebulization in a vibrating mesh nebulizer (Omron 
NE-U22, OMRON Healthcare, Japan) was determined in terms of size, polydispersity index, LT and AZ 
recovery. Briefly, 2 mL of AZ-nanovesicles at a concentration of 15 μg/mL of AZ were nebulized for 5 
min. The aerosols were collected in a vessel connected to the nebulizer. Nanovesicles size, TL and AZ 
were quantified as stated above, before and after nebulization.
2.10 Stability of AZ-nanovesicles upon storage
Empty nanovesicles and AZ-nanovesicles were stored at 4°C for 6 months. Nanovesicles size 
and ζ potential were determined as stated before, every two months storage
2.11 Statistical analysis
Statistical analyses were performed by one-way analysis of variance followed by Dunnet’s test 
using Prisma 4.0 Software (Graph Pad, CA, USA). The p-value of <0.05 was considered statistically 
significant: *p < 0.05; **p <0.01; ***p < 0.001, ****p < 0.0001; n.s. represents non-significant (p > 0.05). 
3. Results
3.1 Structural features of AZ-nanovesicles 
Two types of AZ-nanovesicles were prepared, either starting from 4 or 10 mg/mL AZ. NanoARC-
AZ prepared with 4 mg/mL AZ,  displayed ~ 69 % TL and ~ 47 %  AZ recovery; TL and AZ recovery for 
nanoL-AZ on the other hand, resulted lower:  69 % and 35 % respectively (Table 1). The  potential of 
nanoARC-AZ was shifted towards a less negative value compared to that of nanoARC, probably 
because of electrostatic neutralization between negatively charged archaeolipids and positively charged 
AZ amine groups at pH 7.4. No differences were found in  potential of nanoL and nanoL-AZ. AZ-
nanovesicles prepared from 10 mg/mL AZ on the other hand, due to their lower TL recovery higher 
mean size, PDI, and structural instability (AZ precipitation upon stored along 48 h at 4°C) than those 
prepared with 4 mg/mL, were excluded from further assays.
Table 1. Structural features of nanovesicles 















nanoARC 0 7.6 ± 0.1 182 ± 11 0.18 ± 0.02 -38.7 ± 2.0 
nanoARC-AZ 4 1.9 ± 0.1 6.9 ± 1.4 28 ± 5 168 ± 26 0.23 ± 0.10 -31.2 ± 0.8** No
nanoARC-AZ 10 4.9 ± 2.2 5.4 ± 0.4 93 ± 47 192 ± 21 0.26 ± 0.01 -31.4 ± 5.2** Yes
nanoL 0 6.2 ± 0.5 143 ± 4 0.10 ± 0.01 -6.0 ± 0.9
nanoL-AZ 4 1.4 ± 0.1 6.9 ± 0.5 20 ± 1 172 ± 26 0.17 ± 0.08 -7.1 ± 2.7 No
nanoL-AZ 10 3.6 ± 3.0 4.3 ± 2.4 85 ± 34 260 ± 37**** 0.59 ± 0.10**** -5.3 ± 2.4 Yes
Data are expressed as mean ± SD from three independent batches. TL: total lipids; PDI: 
polydispersity index; SD: standard deviation; Yes: pellet formation after storage at 4°C No: no 
observation of pellet formation after storage at 4°C. Significant differences were determined between 
empty and AZ-nanovesicles.
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Cryo-EM analysis was performed on AZ-nanovesicles. A representative image of nanoL/nanoL-
AZ is shown in Figure 1 (a and b), since no differences were found between the two samples. 
Overlapped spherical unilamellar and multilamellar structures of sizes between ~50 nm and ~130 nm 
were observed. Using ImageJ® software, the bilayer thicknesses were estimated in 6.0  0.5 nm 
medium size, in good agreement with SAXS results (see below). nanoARC are seen in Figure 1 (c and 
d). A considerable number of unilamellar structures were found accompanied by a few multilamellar 
structures, in good agreement with SAXS curves. In contrast to nanoARC-AZ, nanoARC displayed 
rounder morphologies, of sizes variable between ~50 nm and 130 nm, and an estimative medium bilayer 
thickness of ~4.2  0.5 nm, in good agreement with SAXS results. nanoARC-AZ are seen in Figure 1 (e 
and f) as mainly unilamellar elliptical nanovesicles, with scarce oligolamellar structures, of sizes between 
50 nm and 150 nm mean bilayer thickness of ~ 3.9  0.5 nm, reasonably in accordance with SAXS 
results. 
Figure 1. Cryo-EM images of nanoL/nanoL-AZ (a and b), nanoARC (c and d) and nanoARC-AZ (e 
and f). 
The effect of AZ in order or fluidity of AZ-nanovesicles bilayers, was determined by GP and FA of 
the dye Laurdan, and by SAXS. As shown in Table 2, neither bilayer order nor fluidity were modified in 
nanoL-AZ, suggesting that AZ was trapped within the aqueous compartment of nanoL. On the other 
hand, the increased GP of nanoARC-AZ indicated that AZ ordered the nanoARC bilayer; the unchanged 
FA showed that AZ did not modify its fluidity. The increased order would be owed to AZ partitioning 
within nanoARC bilayers. These results were confirmed and amplified by SAXS measurements. Figure  
2a shows the SAXS curves of nanoL (circles) and nanoL-AZ (squares), without significant changes in 
the quite well-defined peaks at q ~ 0.085Å-1 and ~0.170 Å-1 (the scattering curves were vertically shifted 
to clarify the visualization). The presence of sharp peaks in scattering curves at very specific positions, 
like the ones reported herein, which is q and 2q, for q ~ 0.085Å-1 and ~0.170 Å-1, respectively, is a 
fingerprint of multilamellar structures. Instead, the SAXS curves of nanoARC (circles) and nanoARC-AZ 
(squares) in Figure 2b, showed a shift of the first minimum at q ~ 0.045 Å-1 to circa q ~ 0.06Å-1, 
respectively, considered as a clear evidence of structural interaction between AZ and nanoARC bilayers.  
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Additional structural differences between nanoARC and nanoL were indicated by the absence of 
multilamellar structures. 
Table 2. Laurdan GP and FA of nanovesicles
Figure 2: SAXS curves of nanoL [circles], nanoL-AZ [squares] (a) and nanoARC [circles], nanoARC-
AZ [squares] (b).
To further characterize the role of AZ into the structure of nanoARC-AZ, the scattering curves of 
nanoARC and nanoARC-AZ were analysed employing the theoretical model described in section 2.4 
(solid lines in Figure 2b). Both scattering curves could be fitted using the well-kwon unilamellar model, 
already described in the literature.38,39,47 Our analysis showed that the presence of AZ induced a 
shrinking in the membrane thickness,  that decreased from ~ 48 Å in nanoARC to 43 Å in nanoARC-AZ, 
respectively. According to the fitting parameters, the most affected structures were the polar heads and 
the region, showing parameters that, in the presence of AZ, decreased from 9.5 Å to 8.2 Å and from 𝑅𝐶𝐻3
2.9 Å to 1.7Å respectively. Interestingly, AZ did not affect the remaining fitting parameters (Table 3). 
Table 3. Small angle scattering fitting parameters from nanoL, nanoL-AZ, nanoARC and nanoARC AZ 
suspensions in NaCl-Tris buffer.
nanoL & nanoL-AZ nanoARC nanoARC-AZ
model 1 model 2 -- --
w (%) 0.42 ± 0.01 0.58 ± 0.03 -- --
Sample GP FA
nanoARC -0.455 ± 0.013 0.156 ± 0.011
nanoARC-AZ -0.337 ± 0.015 0.164 ± 0.002
nanoL 0.385 ± 0.012 0.218 ± 0.001
nanoL-AZ 0.380 ± 0.006 0.215 ± 0.002
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 (Å)𝑅𝑝𝑜𝑙 15.6 ± 0.1 9.5 ± 1.0 8.2 ± 0.6
 (Å)𝑅𝐶𝐻2 11.7 ± 0.5 11.4± 1.0 11.4 ± 0.1
 (Å)𝑅𝐶𝐻3 2.5 ± 0.6 2.9 ± 0.8 1.7± 0.4
 (e/Å3)𝜌𝑝𝑜𝑙 0.41 ± 0.1 0.44 ± 0.02 0.44 ± 0.02
 (e/Å3)𝜌𝐶𝐻2 0.28 ± 0.1 0.30 ± 0.01 0.30 ± 0.01
 (e/Å3)𝜌𝐶𝐻3 0.20 ± 0.1 0.21 ± 0.01 0.21 ± 0.01
Thick 59.6 ± 0.8 47.8 ± 1.0 43.0 ± 0.7
N 3.0 ± 1.0 -- -- --
d (Å) 74.7 ± 0.1 -- -- --
 Caillè (x10-2) 5.7 ± 0.7 -- -- --
w is the weight of each model, being model 1 the MLV  and model 2 the unilamellar one, Rpol is the 
polar head thickness;  is the acyl chain length;  is the, methyl length; ,  and  are 𝑹𝑪𝑯𝟐 𝑹𝑪𝑯𝟑 𝝆𝒑𝒐𝒍 𝝆𝑪𝑯𝟐 𝝆𝑪𝑯𝟑
the respective electron densities (being the electron density of the solution equal to  = 0.333 e/Å3); 𝝆𝑪𝑯𝟑
Thick is the bilayer thickness; N and d are the number and average distance among the center-to-
center bilayers in one-dimensional lamellar stacking, respectively; ηCaillé is the Caillé parameter.
The same analysis was performed on nanoL and nanoL-AZ, employing the modified Caillè 
Theory.  Table 3 shows the best fitting parameters related to the solid lines on Figure 2a. SAXS data 
show curves without statistical differences between nanoL and nanoL -AZ, the fitting parameters thus 
being also the same. Such finding corroborates with a non (or almost undetectable) interaction of AZ 
and nanoL bilayer.
3.2 Activity of AZ-nanovesicles against PAO1 and S. aureus
Antimicrobial activity of AZ and AZ-nanovesicles on PAO1 and S. aureus was measured by 
determining MIC and MBC on planktonic bacteria and inhibition of biofilm formation. There were also 
determined their disruptive activity on pre-formed biofilm and the bacterial viability in the biofilm. S. 
aureus was included as an example of Gram-positive species, that together with Gram-negative P. 
aeruginosa and Burkholderia cenocepacia are the major opportunistic pathogens implicated in 
pulmonary infection.48 
MIC and MBC of AZ and AZ-nanovesicles are shown in Table 4. It was found that, despite of the 
poor in vitro activity reported for AZ against PAO1 the bacteriostatic and bactericidal activities of AZ-
nanovesicles on PAO1, were higher than those of AZ.49 In comparison, an increased bactericidal activity 
of nanoARC-AZ, higher than those of nanoL-AZ and AZ was found on S. aureus. Void nanoL and 
nanoARC did not show antibacterial activity even up to 2.3 mg TL/mL.
Table 4. MIC and MBC of AZ-nanovesicles on 
planktonic S. aureus and PAO1
S. aureus PAO1
MIC MBC MIC MBCSample (µg/mL) (µg/mL) (µg/mL) (µg/mL)
AZ 4 256 32 64
nanoL-AZ 4 256 16 16
nanoARC-AZ 4 64 8 16
Below the MIC concentration, AZ-nanovesicles partly inhibited PAO1 and S. aureus biofilm 
formation, while AZ had no inhibitory activity (Figure 3a and b).  
It was also found that AZ-nanovesicles disrupted the PAO1 biofilm biomass more efficiently than 
AZ (Figure 4a). Besides, from 32 g/mL AZ, AZ-nanovesicles displayed higher antibacterial activity in 
the biofilm than AZ (Figure 4b). No significant differences were found between nanoARC-AZ and 
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nanoL-AZ. Overall, AZ-nanovesicles had higher antibacterial activity in biofilms and disrupted PAO1 
biofilms at lower concentrations than AZ.  Neither AZ not AZ-nanovesicles, on the other hand, disrupted 
the S. aureus preformed biofilm (Figure S.2a); this was accompanied by a strong antibacterial activity, 
that was independent from AZ concentration (Figure S.2b). Since AZ-nanovesicles neither disrupted S. 
aureus biofilm nor displayed higher antibacterial activity than AZ, the following assays were performed 
only on PAO1. 
Figure 3. Inhibition of biofilm formation upon 24 h incubation with AZ or AZ-nanovesicles with planktonic 
PAO1 (a) and S. aureus (b).
Figure 4. Disruption of preformed biofilm (a) and antibacterial activity (b) of PAO1 upon 24 h incubation 
with AZ or AZ-nanovesicles. 
3.3 Activity of AZ-nanovesicles against PAO1: virulence factors, effect of mucins and 
biofilm penetration
Different from Solleti et al.,27 below the MIC concentration (0.5 g/mL AZ), AZ-nanovesicles did 
not show higher inhibitory activity of virulence factors (proteases and lipase) than AZ (Figure 5).
The presence of mucins reduced the magnitude of  potential of nanoARC-AZ from -35 mV to ~ 
-9 mV, whereas that of nanoL-AZ remained unaffected (Figure 6c).  The mixture of nanoL-AZ and 
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mucins on the other hand, showed 2 shoulders with maximum in ~75 and ~150 nm, both of size higher 
than mucins alone and nanoL-AZ alone (Figure 6a). The mixture of nanoARC-AZ and mucins instead, 
showed two peaks, the one of nanoARC-AZ (~90 nm) and the other corresponding to the medium size 
of mucins (~30 nm) (Figure 6b). Identical results were observed for mixtures of mucins and void 
nanovesicles. The reduced  potential and size enlargements suggest that upon contact, mucins 
wrapped nanoARC and nanoL surfaces. Additionally, dropped on the surface of a mucin layer, 
nanovesicles were observed to penetrate across the media at different speeds; as seen in Figure 6d, 
nanoL made it faster than nanoARC: 80 % of nanoL crossed the layer in 5 h whereas the same 
proportion of nanoARC made it in 10 h. In our experimental conditions of ~1x 107 bacteria/mL per ~1,88 
x 108 nanovesicles,  roughly estimated assuming  103 daltons mean MW of lipids for 150 nm mean sized 
nanovesicles (S. 3),  mucins were observed to increase nanoARC adhesion to PAO1 surface from 10 
to 20 %, the same adhesion percentage of nanoL (Figure 7). Mucins finally, slightly decreased the 
antibacterial activity of AZ-nanovesicles (at 16 g/mL nanoL-AZ, and at 16 and 32 g/mL nanoARC-
AZ), while that of AZ remained unaffected (Figure 8). Overall, mucins increased the nanoARC-AZ 






















































Figure 5. Inhibitory activity of lipase and protease on PAO1 upon incubation with AZ or AZ-
nanovesicles. Significant differences with control (*) and between samples (#). 
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Figure 6. Changes in mean size (a and b) and  potential (c) of AZ-nanovesicles upon 60 min contact 
with mucins (MUC), mucin:nanovesicles 1:1 w:w at 37°C. RhPE-nanovesicles diffusion across a mucin 
layer within a Transwell system (d). 
Figure 7. Adhesion of RhPE-nanovesicles on planktonic PAO1 in the presence or absence of mucins 
(MUC), upon 1 h incubation at 37°C and 250 rpm. 
Figure 8. Anti-PAO1 activity of AZ and AZ-nanovesicles in the presence or absence of mucins (MUC) 
upon 24 h incubation at 37°C.
The confocal fluorescence microscopy images showed that within 1 h the penetration of 
nanoARC-RhPE in preformed PAO1 biofilms carried ~7 folds more mass [assuming the fluorescent dye 
was not released, the higher fluorescence intensity across the biofilm depth is indicative of increased 
mass penetration] than nanoL-RhPE  (Figure 9b). In absence of AZ (an antibiotic displaying biofilm 
disruptive activity), nanoARC-RhPE penetrated the biofilm matrix displaying a homogeneous 
distribution pattern that co-localized with Hoechst; the lagoons/discontinuities in bacteria organization 
suggested the occurrence of fast biofilm disruption, exclusively owed to nanoARC bilayers (Figure 9a). 
50 The structural disorganization was observed to increase with time, faster and more pronounced by 
nanoARC-RhPE, less pronounced and slower by nanoL-RhPE upon 24 h (Figure 9c). 
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Figure 9. Orthogonal images from confocal microscopy of preformed PAO1 biofilm after 1 and 24 h 
incubation with nanoARC-RhPE and nanoL-RhPE. Biofilms were stained and visualized using Hoechst. 
The middle square images are a layer of the biofilm z-stack with the maximum fluorescence intensity 
of RhPE. The panels on the right and bottom are the y-stack and x-stack respectively (a). Quantification 
of nanovesicles penetration within PAO1 biofilm after 1 h (b) and 24 h incubation (c), RhPE FI was 
normalized against Hoechst FI.
3.4 Toxicity of AZ-nanovesicles on human cells 
The cytotoxicity of AZ-nanovesicles on A549 and THP-1 cells was determined by the MTT 
method. Upon 24 h, neither free AZ not AZ-nanovesicles up to 225 µg AZ/mL and 900 µg TL/mL were 
observed to decrease A549 and THP-1 cells viability (Figure 10 a and b). 
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Figure 10. Cell viability measured by MTT upon 24 h incubation with AZ or AZ-nanovesicles on A549 
(a) and THP-1 eukaryotic cell lines (b).  Samples and control have no significant differences p > 0.05.
3.5 Structural stability of AZ-nanovesicles upon nebulization  
The ability of nanovesicles to retain colloidal structure against nebulization shear forces, was 
determined by comparing nanovesicles population size, PDI, AZ and TP content before and after 
nebulization.  It was observed that nebulized nanoL-AZ displayed 6 and 4 folds higher mean size and 
PDI, respectively, than before nebulization; besides, only 50 % of TL was recovered whereas the total 
content of AZ was lost (Figure 11). On the other hand, nebulized nanoARC-AZ retained mean size, 
experiencing a slight increase in PDI, whereas more than 90% of AZ and TL was recovered in the 
nebulized.  
3.6 Structural stability of AZ-nanovesicles upon storage 
It was observed that upon 2 months storage at 4°C, the colloidal stability of nanoARC-AZ was 
higher than that of nanoL-AZ: nanoARC-AZ retained mean population size and PDI, after 6 months 
these parameters increased in lower extent that for nanoL-AZ (Figure 12). 
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Figure 11. AZ-nanovesicles structural stability upon nebulization (a) and AZ and TL recovery after 
nebulization (b).
Figure 12. AZ-nanovesicles structural stability upon 2-6 months storage at 4°C. 
4. Discussion
This work was aimed to design, characterize the structural features, and screen the antibacterial 
performance of AZ loaded nanoARC suitable for aerosolization. To the best of our knowledge, it 
constitutes the first report of an inhalable AZ in lipid nanocarrier.  
Here, nanoARC-AZ were prepared employing the simple thin film hydration method; the 
archaeolipid bilayer trapped AZ, increasing its concentration in aqueous suspension by 760 folds, in a 
highly stable fashion; nanoL-AZ increased AZ in a comparable extent.  
NanoARC-AZ and nanoL-AZ displayed lower MIC and MBC on PAO1, than AZ. The ability of 
nanovesicles to associate with bacterial surface, as revealed by flow cytometry, would be responsible 
of the higher biofilm disruptive activity and antibacterial in biofilm activity of AZ-nanovesicles; those were  
important findings since P. aeruginosa, living as a biofilm, was shown to be as much as 1,000 times 
more resistant to antibiotic treatment than its planktonic counterpart.51 Previous studies had already 
showed the fusion/association between liposomes and Pa surface.52 Surface association would reduce 
the time for released AZ to diffuse from AZ nanovesicles towards the surface of planktonic bacterial 
bodies.  Free AZ instead, bioavailable only at low concentration, would have to diffuse longer distances 
to get the bacteria surface.  
As expected, since planktonic Pa in exponential phase are marginally affected by AZ49, AZ-
nanovesicles poorly inhibited the biofilm formation, an assay performed on bacteria growing in 
exponential phase.  In the same trend, below the MIC, neither AZ nor AZ-nanovesicles affected the 
mobility of planktonic bacteria, whereas nanoARC-AZ barely reduced the production of virulence factor 
lipases. Instead, opposite to its effect on planktonic bacteria, AZ exerts antibacterial activity against Pa 
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living in stationary phase within biofilms.49 That explains why AZ nanovesicles more efficiently disrupt 
the structure of preformed biofilm, and displayed higher antibacterial activity in the biofilm than AZ. 
The presence of mucins has been already reported to inhibit the anti-Pa activity (32 folds higher 
MBC) of liposomal aminoglycosides of size comparable to that of AZ-nanovesicles.53 Opposite to that, 
we found that mucins would not constitute appreciable barriers neither to the access to bacterial surface 
not for the antibacterial activity of AZ-nanovesicles. Mucus of the airways may either trap particulate 
material or the three-dimensional network of mucins polymers may be penetrated by particles.54 
Mucopenetrating nanovesicles access to the deeper mucin layer, being locally retained by longer time 
than mucoadhesive ones.55,56 We found here that nanoARC penetrated slower than nanoL across the 
mucin layer. Because of their comparable size (~ 150 nm), the slowness of nanoARC could be ascribed 
to a higher interaction by hydrogen bonding between surface sugars headgroups from TPA in nanoARC 
and mucins.54 Additionally, mucins neither decreased the association between AZ nanovesicles and 
PAO1 surface, nor their antimicrobial activities. The exception occurred with low AZ nanovesicles 
concentration, where their antibacterial activity decreased toward that of AZ. This fact suggests that 
below a threshold of AZ-nanovesicles/bacteria ratio (at 64 µg/mL for nanoARC-AZ), mucins hampered 
the association of AZ-nanovesicles to bacterial surface. Hence, AZ released from distant non-associated 
AZ nanovesicles, had to diffuse longer distance across the media, to get bacterial surface. Even so, the 
CFU/mL resultant from 64 µg/mL nanoARC-AZ was inferior to that of AZ. This could be owed to the 
highly concentrated AZ depot character of nanoARC-AZ, whose AZ release profile into the bacterial 
microenvironment, would kill it more efficiently than AZ or nanoL-AZ. 
 We observed overall, that despite of improving the effect of AZ, no significant differences were 
found between nanoARC-AZ and nanoL-AZ in terms of AZ/lipids ratio, MIC, MBC, PA surface 
association mucopenetration, biofilm disruption and bactericidal activity within the biofilms. Despite of 
that, in this work 3 competitive advantages of nanoARC matrix compared to nanoL, were revealed. The 
first was the ability of nanoARC to quickly penetrate a preformed biofilm of PAO1. Within 1-hour 
nanoARC penetrated deeper and in higher extent than nanoL. NanoL on the other hand, was observed 
to be aggregated along penetration. It took 24 h the biofilm disruptive activity of nanoL to became 
comparable to that of nanoARC, though repeating the less penetrating pattern. The two reminder 
advantages resulted from the interaction between nanoARC bilayer and AZ. Archaeolipids composing 
nanoARC bilayers, are amphipathic cylindrical molecules having sn2,3 polyisoprenoid chains bonded 
by ether linkages to the glycerol backbone.  Methyl groups perpendicular to the longitudinal molecule 
axis, are responsible for the high transverse area of archaeolipids and features such as high disorder of 
the low lateral mobility bilayers.57 The archaeolipids architecture mimics that of isostearic acid, a fatty 
esters mixture consisting mainly of methyl branched isomers of octadecanoic acid used as surfactant, 
cleanser and binder in pharmaceutics and cosmetics.58 Importantly, the main component of H. 
tebenquichense polar lipids, is the 2,3-di-O-phytanyl-snglycero-1-phospho-(3'-sn-glycerol-1'-
methylphosphate) (PGP-Me), an archaeolipid displaying a double negative charge at physiological pH, 
that is also a ligand for SRA1.  PGP-Me containing nanoARC therefore, are naturally targeted to cells 
expressing SRA1. The combination of such unique biophysical  and pharmacodynamics features of 
nanoARC bilayers,  was recently exploited to trap difficult to dissolve in water drugs, such as the 
immunomodulator imiquimod.59 
Despite of the AZ: lipid w:w ratios of  nanoARC-AZ (0.28) (vs (0.20) from nanoL-AZ 
nanoliposomes made of ordinary phospholipids used as a control)  were comparable and in the order 
of those previously reported for other AZ vesicular formulations (~0.2427 and ~0.2360), the interaction 
between AZ and nanoARC bilayers was unique, and different from that occurring within nanoliposomes, 
where AZ remained dissolved/precipitated within the aqueous space.  The  potential values, together 
with the structural data provided by GP, FA and SAXS, showed that AZ associated to nanoARC bilayers 
consisted of a  combination of electrostatic interaction between negatively charged nanoARC surface 
and the two tertiary amines of  ~ 8.7 and  ~ 9.3 pKa from dicationic AZ61 with trapping within the interface 
and the inner most methyl groups.  The nature of AZ association was key to define the structural stability 
of nanoARC-AZ upon storage and nebulization stress. 
Opposite to nanoL-AZ, nanoARC-AZ experienced minimal increased size and PDI after 6 months 
at 4°C. This is important because enlarged nanovesicles, besides of losing inner content, may 
experience hampered mucopenetration56 and biofilm penetration45. The second advantage was thus the 
higher stability of nanoARC-AZ during storage.  But the last and most important one, was that only 
nanoARC-AZ were structurally stable to nebulization stress. The aqueous suspensions of AZ 
Page 19 of 24































































nanovesicles exhibited comparable anti-PAO1 activity. Upon nebulization however, the structural lability 
of nanoL-AZ made them polydisperse, enlarged and depleted from AZ, presumably, upon the action of  
shear forces needed to produce nebulized water microdroplets.62,63 Instead, negatively charged PGP-
Me in nanoARC-AZ bilayer, attracted positively charged AZ; that interaction, combined with physical 
trapping within archaeolipid bilayer, maintained the association between AZ and archaeolipid matrix 
during bilayer disruption along nebulization. Liposomal antibiotics are known to display higher 
antibacterial activity on biofilms than free antibiotic, because of their ability to penetrate the biofilm 
structure. The prolonged contact with liposomal depots from where antibiotic is released, results in an 
improved activity against bacteria in biofilm.64,65 
A study published 2006 showed that Zithromax, an injectable highly concentrated AZ aqueous 
solution, could be aerosolized employing jet nebulizers.17  Because of the low water solubility of AZ base  
(0.0025 mg/mL at 25° C)66, the AZ  dihydrate  used in such injectable solution requires of massive 
amounts of citric acid and sodium hydroxide as inactive ingredients.67 Theoretically, injectable 
formulations of AZ can be nebulized.68 In practice however, preservatives and admixtures comprised in 
injectable formulations may cause bronchospasm, cough, or occlusion of the expiratory filter and 
contribute to suboptimal drug deposition.69 Upon nebulizing a 100 mg AZ/mL dilution of Zithromax, the 
emitted AZ concentration was reduced to nearly the half, 55 mg AZ/mL. The poor stability of highly 
concentrated AZ solutions (only 24 h at T < 30°C), together with high salt concentrations led to AZ 
precipitation and clogging (as suggested by the reduced AZ emitted dose), probably hampering a 
succeeding nebulization. No further reports on nebulized AZ were published in the last twelve years, 
probably because of these drawbacks.  
In this work, 2 mL of 15 μg/mL nanoARC-AZ were nebulized along 5 min at 0.25 mL/min, resulting 
a dose of nearly 30 μg AZ per 110 μg lipids. This is a relatively diluted suspension of AZ compared to 
the used by Hickey et al., 200617, nearly 6,600 folds higher. However, different to AZ or nanoL-AZ, 
nanoARC-AZ could be conserved as a stable suspension to be nebulized without visible clogging of the 
vibrating mesh, retaining the association between AZ and nanoARC. The nanoARC matrix deeply and 
homogeneously penetrated the PAO1 biofilms, nanoARC-AZ being efficient antibacterial agent at doses 
compatible with 5 minutes nebulization.
5. Conclusions
Ordinary lipid bilayers such as that made of 3:1 w: w HSPC:Chol used in this work, are unsuitable 
as nebulized AZ nanocarriers.  The novelty presented here is that nanoARC bilayers, lacking Chol 
cholesterol and artificially hydrogenated lipids, may be successfully used as nebulized AZ nanocarriers. 
NanoARC thus, may result as suitable alternative to the nebulized hard liposomes in advanced clinical 
trials and recently approved by the FDA.19-22 The efficient association between AZ and nanoARC bilayer, 
was maintained against shear forces of nebulization: nanoARC-AZ remained structurally stable in 
suspension along storage, and AZ remained trapped  into nanoARC bilayer with no need of highly 
concentrated acids and bases. In vivo, because of being SRA1 targeted formulations, nanoARC-AZ 
may have synergic immunomodulatory effects, aiding to reduce the inflammation associated to chronic 
inflammation. NanoARC-AZ, the first nebulized AZ-nanovesicle formulation, enhanced the anti-PAO1 
activity of AZ at doses below the cytotoxicity on A549 cells and human THP-1 derived macrophages. 
Deeper insights on the effect of nebulized nanoARC-AZ, a formulation that combines 
bacteriostatic/bactericidal activity with SRA1 targeting, deserve to be explored on a suitable disease 
model.  
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